- |||||||||| dexamethasone / Generic mfg.
Journal: The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients. (Pubmed Central) - Nov 15, 2022
Our data showed that dexamethasone therapy protocol affected COVID-19 prognoses in cancer patients, and it is preferable to not discontinue therapy after infection. A rigorous prospective comparison between early and late dexamethasone dosing is needed to determine the best protocol for treatment.
- |||||||||| prednisolone / Generic mfg., doxycycline / Generic mfg., cyclosporine / Generic mfg.
Journal: Negative-pressure wound therapy as an adjunct to treating pyoderma gangrenosum. (Pubmed Central) - Nov 15, 2022
After multidisciplinary discussion, involving breast surgeons, oncology, dermatology and tissue viability, doxycycline was commenced alongside a portable negative-pressure device with twice weekly tissue viability input. The introduction of this device resulted in a rapid reduction in the wound size and facilitated healing with an excellent outcome.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Journal: Anti-NMDAR encephalitis with GFAPα IgG: a case report. (Pubmed Central) - Nov 15, 2022
However, because this was a single case study, caution should be exercised when interpreting the observations. Since the patient was diagnosed with autoimmune encephalitis, intravenous methylprednisolone was administered, which yielded a positive outcome.
- |||||||||| dexamethasone / Generic mfg., metformin / Generic mfg.
Review, Journal: Recent advances on small molecules in osteogenic differentiation of stem cells and the underlying signaling pathways. (Pubmed Central) - Nov 15, 2022
These pathways include more well-known pathways including BMP/Smad, Wnt, and Hedgehog as well as ancillary pathways including estrogen signaling and neuropeptide signaling. In this paper, we review the recent data on small molecule-mediated osteogenic differentiation, possible adjunctive agents with these molecules, and the signaling pathways through which each small molecule exerts its effects.
- |||||||||| dexamethasone / Generic mfg.
Journal: Energy Landscapes of Supramolecular Peptide-Drug Conjugates Directed by Linker Selection and Drug Topology. (Pubmed Central) - Nov 15, 2022
The choice of linker, which alters the orientation, rotational freedom, and number of stereoisomers of the prodrug in the final sPDC, impacts the mechanism and energetic barrier of assembly as well as the nano/macroscale properties of the resultant supramolecular materials. Accordingly, this work demonstrates the nonzero energetic contributions of the drug and its linker to sPDC self-assembly, provides a quantitative exploration of the sPDC free energy landscape, and suggests design principles for the enhanced control of sPDC nanomaterials to inform future applications as therapeutic drug carriers.
- |||||||||| Journal: Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management. (Pubmed Central) - Nov 15, 2022
Accordingly, this work demonstrates the nonzero energetic contributions of the drug and its linker to sPDC self-assembly, provides a quantitative exploration of the sPDC free energy landscape, and suggests design principles for the enhanced control of sPDC nanomaterials to inform future applications as therapeutic drug carriers. Patients with asthma initiating triple therapy with FF/UMEC/VI had significantly better adherence and persistence compared with MITT initiators.
- |||||||||| budesonide / Generic mfg.
Journal: Stabilization of cell-cell adhesions prevents symmetry breaking and locks in pluripotency in 3D gastruloids. (Pubmed Central) - Nov 15, 2022
This correlates with reduced phenotypic and molecular cell heterogeneity, persistence of E-CADHERIN at the cell-cell interface, and cell aggregate compaction. Our findings reveal that cell-cell adhesion properties control symmetry breaking and cell fate transition in 3D gastruloids and suggest a potential adverse effect of budesonide on embryo development.
- |||||||||| dexamethasone / Generic mfg., nitroglycerin / Generic mfg.
Journal: HELLP syndrome manifesting as abnormal fetal umbilical artery blood flow and rapidly worsening laboratory indexes: A case report. (Pubmed Central) - Nov 15, 2022
Dexamethasone was given after admission to our hospital to promote fetal lung maturation, magnesium sulfate was given to protect fetal brain nerves, and maternal blood pressure was closely monitored...Magnesium sulfate was given immediately to prevent spasm, and nitroglycerin was administered intravenously against hypertension...Our case highlights that HELLP syndrome is a serious complication, and it should be diagnosed carefully and not arbitrarily on the basis of some abnormal indicators and stable clinical manifestations. Accurate early identification, active monitoring and management are essential for improving prognosis and avoiding maternal or infant mortality.
- |||||||||| budesonide/formoterol / Generic mfg.
‘Smart inhaler’ in routine clinic practise: Is there a role in mild and moderate asthma management? (Westminster, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_537;
We report the utility of using ‘smart’ inhaler technology to objectively address adherence with inhaled therapy among patients with mild to moderate asthma.Methods Consecutive consenting patients (age ≥ 18) adherent to therapy based on clinical assessment had their LABA/ICS combination inhaler/s switched over to budesonide/formoterol turbohaler (Symbicort) with sensor...Results depicted in table 1.View this table:View inline P184 Table 1 The demographics of participants and concordance recorded together with the mean duration of smart inhaler useConclusion ‘Smart’ inhalers used in routine clinical practice may help in achieving better asthma control both by identifying sub-optimal adherence, which can then be addressed. However, smart inhaler use alone does not guarantee adherence and role of clinicians in monitoring concordance data and providing suitable education remains very important.
- |||||||||| Ventolin (albuterol) / GSK
Partnering patients on climate change; assessing patients’ understanding of the carbon footprint of inhalers (Moore, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_321;
We have found comparisons with the number of miles travelled in a car to be readily understood. Providing this information in a comprehensible way will empower patients to make decisions about the selection, use and disposal of their inhalers, which would minimise their environmental impact without losing control of their asthma.
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Reducing the environmental impact of pressurized metered dose inhalers: relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate with novel propellant formulations in healthy subjects (Moore, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_319;
P1
The objective of this study was to evaluate the relative bioavailabilities of the components in the fixed-dose combination of budesonide, glycopyrronium, and formoterol fumarate dihydrate (BGF) between three different propellant formulations of BGF MDI, 160/7.2/5 µg per actuation.Methods Healthy subjects aged 18 to 60 years were randomized into a single-blind, three-period, single-dose, single-centre, crossover study (NCT04600505)...The combination of BGF when administered as single doses in three different propellant formulations demonstrated an acceptable safety profile and was well tolerated in the studied population. Both novel, low global warming-potential propellants may be viable for use in a clinical setting; therefore, further investigation in larger studies is warranted.Please refer to page A210 for declarations of interest related to this .
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines (Moore, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_318;
Consequently, we estimate to transition to the new propellant in a portfolio of pMDI products across all markets, will take at least 5 years after the first product launch. However, a next generation of pMDIs with near-zero GWP propellant offers a way to resolve the climate and other environmental impacts posed by these devices without restricting patient choice or compromising clinical outcomes.
- |||||||||| dexamethasone / Generic mfg.
ZFP36L1 and ZFP36L2 deficiency contribute to steroid refractoriness and epithelial remodelling in severe asthma (Rutherford, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_314;
We employed Frac-seq in primary BECs depleted of L1 and L2 (mimicking SA) vs control and stimulated with dexamethasone...RIP demonstrated that ZFP36L1/L2 bind to their mRNA targets in a steroid-dependent manner. ZFP36L1/L2 and steroids altered the expression of mRNAs encoding structural proteins, hinting at these RBPS as modulators of epithelial structural changes and steroid poor responsiveness.Conclusions ZFP36L1/L2 are novel modulators of steroid effects in epithelium and may potentially contribute to steroid refractoriness.Please refer to page A210 for declarations of interest related to this .
- |||||||||| nintedanib / Generic mfg.
Predictors of mortality in progressive fibrosing interstitial lung disease patients treated with Nintedanib: real-world data from a single ILD specialist centre (Abbey, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_257;
Longer median duration of Nintedanib administration was also associated with a statistically significant difference in mortality (20 months compared to 7 months, p<0.01). There was no statistically significant difference when considering age at commencement, sex, PFILD subtype or diagnostic criteria, smoking status, comorbidities, oxygen therapy, use of concomitant immunosuppression, acute ILD exacerbations, or radiological pattern.View this table:View inline P23 Table 1 Demographic, clinical, functional, radiological and survival characteristics of PFILD patients treated with NintedanibConclusions In this PFILD cohort, lower baseline FVC and DLCO, higher dose of prednisolone, and shorter duration of treatment with Nintedanib were associated with increased mortality.
- |||||||||| fluticasone / Generic mfg.
Airways oscillometry in asthma diagnosis in treatment naive but symptomatic adults (Westminster, 4th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_249;
Assessment included clinical history, examination, lung physiology (spirometry, reversibility, FeNO, PEFv and bronchial challenge), skin prick testing, serum eosinophils before and after 6–8 weeks of inhaled fluticasone (250µg BD)...However,% predicted values R5 and R20 were both significantly higher in asthma compared to not asthma.View this table:View inline P22 Table 1 Table of results 110 adults from RADicA study diagnosed with ‘asthma’ or ‘not asthma’ with Airways Oscillometry% predicted values for R5, R20 and fres, (geometric mean and 95% CI)Conclusion Our findings suggest that R5 and R20 AO results (as% predicted) were higher amongst symptomatic adults who were subsequently diagnosed with asthma, compared to those with symptoms that were not asthma. Further research is needed to evaluate the role of AO in asthma diagnosis, in particular, thresholds.
- |||||||||| prednisolone / Generic mfg.
Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial) (Windsor, 5th floor) - Nov 15, 2022 - Abstract #BTSWM2022BTS_WM_226;
P4
There were no statistically or clinically meaningful difference in the COPD assessment test, forced expiratory volume in 1 second and the symptom visual analogue scales between participants in the eosinophil-biomarker guided and standard care armsConclusion Reduction of prednisolone therapy, using near-patient testing can be safely performed using an eosinophil-biomarker guided approach in primary care for treatment of an exacerbation of COPD. This should become part of clinical practice.Trial Registration NCT04458636 Please refer to page A208 for declarations of interest related to this .
- |||||||||| budesonide / Generic mfg.
Review, Journal: Corticosteroids in Inflammatory Bowel Disease: Are they still a therapeutic option? (Pubmed Central) - Nov 15, 2022
This review article is not intended to be just a classic review of the indications for corticosteroids. Here we explain the scenarios in which, in our opinion, steroids would not be an appropriate option for our patients, as well as the most frequent mistakes we make in our daily practice when using them.
- |||||||||| dexamethasone / Generic mfg.
Trial completion date, Trial primary completion date: Sphenopalatine Block Versus Greater Occipital Nerve Block in PDPH (clinicaltrials.gov) - Nov 14, 2022
P=N/A, N=120, Recruiting,
Here we explain the scenarios in which, in our opinion, steroids would not be an appropriate option for our patients, as well as the most frequent mistakes we make in our daily practice when using them. Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Nov 2022
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion date, Trial primary completion date, Surgery: Dupilumab for Prevention of Recurrence of CRSwNP After ESS (clinicaltrials.gov) - Nov 14, 2022
P4, N=36, Recruiting,
Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Nov 2022 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Oct 2022 --> Jan 2024
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Enrollment closed, Trial completion date, Trial primary completion date: DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov) - Nov 14, 2022
P3, N=560, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Nov 2028 | Trial primary completion date: Dec 2022 --> Nov 2024
- |||||||||| methylprednisolone acetate / Generic mfg.
Trial completion, Trial completion date: Pain Increases After Shoulder Injection (clinicaltrials.gov) - Nov 14, 2022
P4, N=436, Completed,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Nov 2028 | Trial primary completion date: Dec 2022 --> Nov 2024 Enrolling by invitation --> Completed | Trial completion date: Dec 2022 --> Sep 2022
|
